Compare L3Harris Technologies Inc (LHX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs TG Therapeutics Inc — how do they compare? L3Harris Technologies Inc trades at $236.8 (market cap $44.12B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: L3Harris Technologies Inc is far larger — about 5.4× TG Therapeutics Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and TG Therapeutics Inc for 16 Days on average.
| LHX | TGTX | |
|---|---|---|
Market Cap | $44.12B | $8.16B |
Volume | 1,202,852 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $378.48 | $59.06 |
52-Week Low | $233.63 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $54.56B | $8.37B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.15, up 1.51% on the day, with a bearish technical signal from moving averages but strong fundamental performance, including three consecutive quarterly EPS beats. The company secured major defense contracts totaling over $10.7 billion in September 2026, supporting future revenue growth. Profit margins have improved steadily, with net income margin reaching 7.34% in 2025, and cash flow from operations strengthened to $3.11 billion.
The outlook is positive given robust contract wins and earnings momentum, but risks include ongoing legal investigations and high debt levels. Analyst consensus is strongly bullish with a $340 price target, implying significant upside from current levels, though technical indicators suggest near-term resistance around $238-$240.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
